Annual SGA
$182.34 M
-$14.52 M-7.38%
December 31, 2022
Summary
- As of March 8, 2025, SRNE annual SGA is $182.34 million, with the most recent change of -$14.52 million (-7.38%) on December 31, 2022.
- During the last 3 years, SRNE annual SGA has risen by +$78.78 million (+76.07%).
- SRNE annual SGA is now -7.38% below its all-time high of $196.86 million, reached on December 31, 2021.
Performance
SRNE SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$48.94 M
-$6.04 M-10.98%
June 30, 2023
Summary
- As of March 8, 2025, SRNE quarterly SGA is $48.94 million, with the most recent change of -$6.04 million (-10.98%) on June 30, 2023.
- Over the past year, SRNE quarterly SGA has dropped by -$6.04 million (-10.98%).
- SRNE quarterly SGA is now -10.98% below its all-time high of $54.98 million, reached on March 31, 2023.
Performance
SRNE Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$7.99 B
-$548.10 M-7.37%
June 30, 2023
Summary
- As of March 8, 2025, SRNE TTM SGA is -$7.99 billion, with the most recent change of -$548.10 million (-7.37%) on June 30, 2023.
- Over the past year, SRNE TTM SGA has dropped by -$8.18 billion (-4244.74%).
- SRNE TTM SGA is now -745586.55% below its all-time high of -$1.07 million.
Performance
SRNE TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
SRNE Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.4% | -11.0% | -4244.7% |
| 3 y3 years | +76.1% | -11.0% | -4244.7% |
| 5 y5 years | +375.7% | -11.0% | -4244.7% |
SRNE Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7.4% | at low | -11.0% | +24.0% | -69.7% | at low |
| 5 y | 5-year | -7.4% | +76.1% | -11.0% | +101.7% | -252.7% | at low |
| alltime | all time | -7.4% | >+9999.0% | -11.0% | >+9999.0% | <-9999.0% | at low |
Sorrento Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | $48.94 M(-11.0%) | $193.54 M(+0.4%) |
| Mar 2023 | - | $54.98 M(+39.3%) | $192.74 M(+5.9%) |
| Dec 2022 | $182.34 M(-7.4%) | $39.46 M(-21.3%) | $182.09 M(-7.7%) |
| Sep 2022 | - | $50.16 M(+4.2%) | $197.30 M(+0.9%) |
| Jun 2022 | - | $48.14 M(+8.6%) | $195.63 M(-1.1%) |
| Mar 2022 | - | $44.33 M(-18.9%) | $197.79 M(+0.5%) |
| Dec 2021 | $196.86 M(+69.4%) | $54.68 M(+12.8%) | $196.86 M(+7.4%) |
| Sep 2021 | - | $48.49 M(-3.6%) | $183.33 M(+15.2%) |
| Jun 2021 | - | $50.29 M(+15.9%) | $159.10 M(+19.4%) |
| Mar 2021 | - | $43.39 M(+5.4%) | $133.27 M(+14.7%) |
| Dec 2020 | $116.18 M(+12.2%) | $41.15 M(+69.6%) | $116.18 M(+15.7%) |
| Sep 2020 | - | $24.27 M(-0.8%) | $100.46 M(-1.0%) |
| Jun 2020 | - | $24.46 M(-7.0%) | $101.42 M(-3.2%) |
| Mar 2020 | - | $26.30 M(+3.4%) | $104.73 M(+1.1%) |
| Dec 2019 | $103.56 M(+62.7%) | $25.43 M(+0.8%) | $103.56 M(+2.9%) |
| Sep 2019 | - | $25.23 M(-9.1%) | $100.66 M(+5.4%) |
| Jun 2019 | - | $27.77 M(+10.5%) | $95.53 M(+21.2%) |
| Mar 2019 | - | $25.12 M(+11.5%) | $78.80 M(+23.8%) |
| Dec 2018 | $63.64 M(+66.0%) | $22.54 M(+12.1%) | $63.64 M(+31.9%) |
| Sep 2018 | - | $20.10 M(+82.1%) | $48.24 M(+25.8%) |
| Jun 2018 | - | $11.04 M(+10.8%) | $38.35 M(+5.3%) |
| Mar 2018 | - | $9.96 M(+39.5%) | $36.41 M(-5.0%) |
| Dec 2017 | $38.33 M(+58.3%) | $7.14 M(-30.1%) | $38.33 M(-7.5%) |
| Sep 2017 | - | $10.21 M(+12.3%) | $41.43 M(+13.6%) |
| Jun 2017 | - | $9.09 M(-23.5%) | $36.48 M(+15.4%) |
| Mar 2017 | - | $11.89 M(+16.1%) | $31.61 M(+30.5%) |
| Dec 2016 | $24.22 M(+20.3%) | $10.24 M(+94.4%) | $24.22 M(+0.4%) |
| Sep 2016 | - | $5.27 M(+24.8%) | $24.11 M(+2.4%) |
| Jun 2016 | - | $4.22 M(-6.1%) | $23.56 M(+5.1%) |
| Mar 2016 | - | $4.50 M(-55.6%) | $22.41 M(+11.3%) |
| Dec 2015 | $20.13 M | $10.13 M(+115.0%) | $20.13 M(+62.5%) |
| Sep 2015 | - | $4.71 M(+53.4%) | $12.39 M(+30.0%) |
| Jun 2015 | - | $3.07 M(+38.4%) | $9.53 M(+8.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | $2.22 M(-7.0%) | $8.82 M(-11.7%) |
| Dec 2014 | $9.99 M(+58.1%) | $2.39 M(+28.7%) | $9.99 M(-1.8%) |
| Sep 2014 | - | $1.85 M(-21.5%) | $10.16 M(+7.9%) |
| Jun 2014 | - | $2.36 M(-30.3%) | $9.43 M(+10.0%) |
| Mar 2014 | - | $3.38 M(+32.0%) | $8.57 M(+33.2%) |
| Dec 2013 | $6.32 M(+293.3%) | $2.56 M(+130.3%) | $6.44 M(+40.3%) |
| Sep 2013 | - | $1.11 M(-26.1%) | $4.59 M(+17.6%) |
| Jun 2013 | - | $1.51 M(+20.6%) | $3.90 M(+47.9%) |
| Mar 2013 | - | $1.25 M(+74.7%) | $2.64 M(+64.2%) |
| Dec 2012 | $1.61 M(+33.7%) | $715.70 K(+67.6%) | $1.61 M(+49.7%) |
| Sep 2012 | - | $427.00 K(+74.6%) | $1.07 M(+33.3%) |
| Jun 2012 | - | $244.60 K(+11.8%) | $804.50 K(-26.0%) |
| Mar 2012 | - | $218.70 K(+20.0%) | $1.09 M(-9.5%) |
| Dec 2011 | $1.20 M(+9.0%) | $182.20 K(+14.6%) | $1.20 M(-7.8%) |
| Sep 2011 | - | $159.00 K(-69.8%) | $1.30 M(-4.0%) |
| Jun 2011 | - | $527.20 K(+58.4%) | $1.36 M(+18.0%) |
| Mar 2011 | - | $332.80 K(+17.1%) | $1.15 M(+4.3%) |
| Dec 2010 | $1.10 M(+102.6%) | $284.10 K(+32.8%) | $1.10 M(-7.9%) |
| Sep 2010 | - | $213.90 K(-33.1%) | $1.20 M(+6.5%) |
| Jun 2010 | - | $319.60 K(+12.2%) | $1.12 M(+35.4%) |
| Mar 2010 | - | $284.90 K(-24.7%) | $829.60 K(+52.3%) |
| Dec 2009 | $544.00 K(+2016.7%) | $378.60 K(+169.5%) | $544.70 K(+1049.2%) |
| Sep 2009 | - | $140.50 K(+448.8%) | $47.40 K(+45.0%) |
| Jun 2009 | - | $25.60 K(-121.6%) | $32.70 K(+27.2%) |
| Dec 2008 | $25.70 K(-89.3%) | -$118.70 K(-194.4%) | $25.70 K(-83.1%) |
| Sep 2008 | - | $125.80 K(+2229.6%) | $151.80 K(+314.8%) |
| Jun 2008 | - | $5400.00(-59.1%) | $36.60 K(-16.4%) |
| Mar 2008 | - | $13.20 K(+78.4%) | $43.80 K(-81.8%) |
| Dec 2007 | $240.60 K(-45.2%) | $7400.00(-30.2%) | $240.50 K(+3.2%) |
| Sep 2007 | - | $10.60 K(-15.9%) | $233.10 K(+4.8%) |
| Jun 2007 | - | $12.60 K(-94.0%) | $222.50 K(+6.0%) |
| Mar 2007 | - | $209.90 K | $209.90 K |
| Dec 2006 | $439.30 K | - | - |
FAQ
- What is Sorrento Therapeutics annual SGA?
- What is the all time high annual SGA for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual SGA year-on-year change?
- What is Sorrento Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly SGA year-on-year change?
- What is Sorrento Therapeutics TTM SGA?
- What is the all time high TTM SGA for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM SGA year-on-year change?
What is Sorrento Therapeutics annual SGA?
The current annual SGA of SRNE is $182.34 M
What is the all time high annual SGA for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual SGA is $196.86 M
What is Sorrento Therapeutics annual SGA year-on-year change?
Over the past year, SRNE annual SGA has changed by -$14.52 M (-7.38%)
What is Sorrento Therapeutics quarterly SGA?
The current quarterly SGA of SRNE is $48.94 M
What is the all time high quarterly SGA for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly SGA is $54.98 M
What is Sorrento Therapeutics quarterly SGA year-on-year change?
Over the past year, SRNE quarterly SGA has changed by -$6.04 M (-10.98%)
What is Sorrento Therapeutics TTM SGA?
The current TTM SGA of SRNE is -$7.99 B
What is the all time high TTM SGA for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM SGA is -$1.07 M
What is Sorrento Therapeutics TTM SGA year-on-year change?
Over the past year, SRNE TTM SGA has changed by -$8.18 B (-4244.74%)